Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Morphic to Present at the Jefferies Global Healthcare Conference By: Morphic Therapeutic via GlobeNewswire June 06, 2023 at 16:05 PM EDT WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the Jefferies Healthcare Conference, including a hosted fireside chat, on Wednesday, June 7, 2023. Fireside Chat InformationDate: Wednesday June 7, 2023Time: 1:00 PM ETA live webcast of the presentation will be available on the Investor section of the Morphic website, or at the link here. An archived replay will be available on the company’s website following the conference. About Morphic TherapeuticMorphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com. ContactsMorphic TherapeuticChris Erdmanchris.erdman@morphictx.com617.686.1718 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Morphic to Present at the Jefferies Global Healthcare Conference By: Morphic Therapeutic via GlobeNewswire June 06, 2023 at 16:05 PM EDT WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the Jefferies Healthcare Conference, including a hosted fireside chat, on Wednesday, June 7, 2023. Fireside Chat InformationDate: Wednesday June 7, 2023Time: 1:00 PM ETA live webcast of the presentation will be available on the Investor section of the Morphic website, or at the link here. An archived replay will be available on the company’s website following the conference. About Morphic TherapeuticMorphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com. ContactsMorphic TherapeuticChris Erdmanchris.erdman@morphictx.com617.686.1718
WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the Jefferies Healthcare Conference, including a hosted fireside chat, on Wednesday, June 7, 2023. Fireside Chat InformationDate: Wednesday June 7, 2023Time: 1:00 PM ETA live webcast of the presentation will be available on the Investor section of the Morphic website, or at the link here. An archived replay will be available on the company’s website following the conference. About Morphic TherapeuticMorphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com. ContactsMorphic TherapeuticChris Erdmanchris.erdman@morphictx.com617.686.1718